Meningioma

Section editor
	Seema Nagpal, MD Stanford University Palo Alto, CA, USA LinkedIn

0 regimens on this page 0 variants on this page

Guidelines

EANO

• 2016: EANO guidelines for the diagnosis and treatment of meningiomas PubMed

NCCN

• NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.

Unresectable, all lines of therapy

Placebo

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Ji et al. 2015 (SWOG S9005)	1992-1998	Phase 3 (C)	Mifepristone	Did not meet primary endpoint of FFS

No active antineoplastic treatment.

References

1. SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701